NCT06456346

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2024-07-16Est. Completion: 2027-09-28

Enrollment target: 300 participants

Locations

Palo Verde Cancer Specialists ( Site 0052), Glendale, Arizona, United States
Los Angeles Cancer Network ( Site 0025), Glendale, California, United States
Stanford Cancer Center ( Site 0024), Palo Alto, California, United States
Exempla Lutheran Medical Center ( Site 0014), Golden, Colorado, United States
Yale University School of Medicine ( Site 0051), New Haven, Connecticut, United States
Parkview Research Center at Parkview Regional Medical Center ( Site 0006), Fort Wayne, Indiana, United States
University of Michigan ( Site 0003), Ann Arbor, Michigan, United States
Optum Care Cancer Center ( Site 0053), Las Vegas, Nevada, United States
Levine Cancer Institute ( Site 0009), Charlotte, North Carolina, United States
Duke University Health System (DUHS) ( Site 0012), Durham, North Carolina, United States
Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013), Winston-Salem, North Carolina, United States
The Ohio State University Wexner Medical Center ( Site 0028), Columbus, Ohio, United States
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8005), Eugene, Oregon, United States

Other microbiome trials you might be interested in

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaPhase 3Recruiting

Essential Thrombocythemia

This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thromb…

Multiple LocationsEst. completion Jun 15, 2029

View Trial →

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPhase 1Recruiting

Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)Post-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis (PMF)

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmaco…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.